Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Net Cash Flow (2020 - 2023)

Candel Therapeutics' Net Cash Flow history spans 4 years, with the latest figure at -$7.6 million for Q4 2023.

  • For Q4 2023, Net Cash Flow fell 6.25% year-over-year to -$7.6 million; the TTM value through Dec 2023 reached -$34.6 million, down 171.9%, while the annual FY2024 figure was $67.2 million, 294.09% up from the prior year.
  • Net Cash Flow for Q4 2023 was -$7.6 million at Candel Therapeutics, up from -$8.9 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $64.1 million in Q3 2021 and bottomed at -$10.8 million in Q1 2023.
  • The 4-year median for Net Cash Flow is -$6.4 million (2021), against an average of $1.1 million.
  • The largest annual shift saw Net Cash Flow soared 2964.06% in 2021 before it plummeted 192.37% in 2023.
  • A 4-year view of Net Cash Flow shows it stood at $16.8 million in 2020, then plummeted by 134.19% to -$5.7 million in 2021, then fell by 24.09% to -$7.1 million in 2022, then fell by 6.25% to -$7.6 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Net Cash Flow are -$7.6 million (Q4 2023), -$8.9 million (Q3 2023), and -$7.4 million (Q2 2023).